Compounds > efavirenz

efavirenz and rifampin

efavirenz has been researched along with rifampin in 114 studies

Research

Studies (114)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (0.88)18.2507
2000's28 (24.56)29.6817
2010's62 (54.39)24.3611
2020's23 (20.18)2.80

Authors

AuthorsStudies
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF1
Hussar, DA1
Alarcón-González, A; Gómez-Mateos, J; León-Jimenez, E; López-Cortés, LF; López-Pua, Y; Pachón, J; Ruiz-Valderas, R; Sarasanacenta, M; Viciana, P1
Back, DJ; Boffito, M; Bonora, S; Di Perri, G; Hoggard, PG; Reynolds, HE; Tija, J1
Patel, A; Patel, B; Patel, J; Patel, K; Rani, S; Shah, N1
Alves, CR; Badaro, R; Brites, C; Netto, EM; Oliveira, AS; Pedral-Sampaio, DB1
Buckley, AR; Buckley, DJ; Desai, PB; Hariparsad, N; Nallani, SC; Sane, RS1
Kiertiburanakul, S; Mahanontharit, A; Manosuthi, W; Prasithsirikul, W; Rattanasiri, S; Ruxrungtham, K; Sankote, J; Sungkanuparph, S; Thakkinstian, A; Vibhagool, A1
Brennan-Benson, P; Harrison, T; Lyus, R; Macallan, D; Pakianathan, M1
Kiertiburanakul, S; Manosuthi, W; Rattanasiri, S; Ruxrungtham, K; Sungkanuparph, S; Thakkinstian, A; Vibhagool, A1
Burger, DM; Droste, JA; la Porte, CJ1
de Campos, AV; Leon, E; Lopez-Cortes, LF; Lozano, F; Marin-Niebla, A; Marquez-Solero, M; Ruiz-Morales, J; Ruiz-Valderas, R; Valiente, R1
Friedland, G; Jack, C; Khoo, S; Lalloo, U1
Caligaris, S; Capone, S; Carosi, G; Carvalho, AC; Cusato, M; De Iaco, G; Manfrin, M; Matteelli, A; Regazzi, M; Tomasoni, L; Villani, P1
Chan-Tack, KM; DiGiacinto, JL; Reynolds, KS; Robertson, SM; Struble, KA1
Chimsuntorn, S; Lueangniyomkul, A; Mankatitham, W; Manosuthi, W; Sungkanuparph, S1
Gibbins, S; Kon, O; O'Donoghue, M; Obiorah, I; Sathia, L; Taylor, G; Walsh, J; Winston, A1
Abrahams, M; Boulle, A; Coetzee, D; Cohen, K; Goemaere, E; Hilderbrand, K; Maartens, G; Mathee, S; Van Cutsem, G1
Boamah, I; Boima, V; Court, MH; Greenblatt, DJ; Kenu, E; Kwara, A; Lartey, M; Oliver-Commey, J; Sagoe, A; Sagoe, KW; Xexemeku, F1
Ainsworth, J; Anderson, J; Back, D; Bansi, L; Dunn, D; Easterbrook, P; Fisher, M; Gibbons, S; Gilson, R; Hill, T; Johnson, M; Khoo, S; Leen, C; Orkin, C; Pillay, D; Pozniak, A; Sabin, C; Stöhr, W; Winston, A1
Cabrera, SE; Cordero, M; Domínguez-Gil, A; García, MJ; Iglesias, A; Valverde, MP1
Anitha, S; Gomathi, C; Hemanth Kumar, AK; Kumar, P; Menon, P; Narendran, G; Rajasekaran, S; Ramachandran, G; Ramesh, K; Swaminathan, S1
Eley, BS; Maartens, G; McIlleron, HM; Meyers, TM; Nuttall, JJ; Ren, Y; Smith, PJ1
Brouwer, AM; Burger, DM; de Lange, W; van der Ven, A; van Luin, M; van Schaik, RH1
Cilliers, K; Donald, PR; Hussey, GD; Labadarios, D; Maritz, JS; McIlleron, H; Schaaf, HS; Smith, P; Willemse, M1
Lalloo, UG1
Burapatarawong, S; Likanonsakul, S; Lueangniyomkul, A; Mankatitham, W; Manosuthi, W; Prasithsirskul, W; Prommool, V; Ruxrungtham, K; Sungkanuparph, S; Tantanathip, P; Thawornwa, U; Thongyen, S1
Eampokarap, B; Kaewsaard, S; Lueangniyomkul, A; Mankatitham, W; Manosuthi, W; Ruxrungtham, K; Sungkanuparph, S; Suwanvattana, P; Tantanathip, P; Thongyen, S; Uttayamakul, S1
Charalombous, S; Churchyard, G; Cohen, K; Dandara, C; Fielding, K; Grant, A; Maartens, G; McIlleron, H; Pemba, L; Smith, P1
Kwara, A; Ramachandran, G; Swaminathan, S1
Djoerban, Z; Setiabudy, R1
Cho, DY; Desta, Z; Jones, D; Ogburn, ET1
Ashton, M; Mukonzo, J; Rekić, D; Röshammar, D1
Court, MH; Dumond, JB; Greenblatt, DJ; Kashuba, AD; Kurpewski, J; Kwara, A; Poethke, P; Tashima, KT1
Chaddha, U; Goray, A; Kumar, AK; Lala, M; Ramachandran, G; Shah, I; Swaminathan, S; Tayal, S1
Cohen, K; Conradie, F; Ive, P; Orrell, C; Sanne, I; Wood, R; Zeinecker, J1
Lueangniyomkul, A; Mankhatitham, W; Manosuthi, W1
Aklillu, E; Bertilsson, L; Burhenne, J; Haefeli, WE; Janabi, M; Minzi, O; Mugusi, F; Mugusi, S; Ngaimisi, E; Riedel, KD; Sasi, P; Suda, A; Ueda, N1
Fox, D; Mallon, P; McMahon, G; O'Connor, R1
Abdool Karim, SS; Botha, JH; Gengiah, TN; Gray, AL; Holford, NH; Naidoo, K1
Aderaye, G; Aklillu, E; Amogne, W; Burhenne, J; Habtewold, A; Lindquist, L; Makonnen, E; Riedel, KD; Suda, A; Ueda, N; Yimer, G1
Manosuthi, W; Wongsawat, J1
Adda, N; Alves, K; Chandorkar, G; Garg, V; McNair, L; Smith, F; van Heeswijk, RP; Yang, Y1
Aarnoutse, RE; Boeree, MJ; Burger, DM; Fillekes, Q; Kibiki, GS; Kisanga, ER; Kisonga, RM; Mleoh, L; Mtabho, CM; Ndaro, A; Semvua, HH; van den Boogaard, J; van der Ven, A1
Khusmith, S; Likanonsakul, S; Manosuthi, W; Shioda, T; Uttayamakul, S; Wichukchinda, N1
Lueangniyomkul, A; Mankatitham, W; Manosuthi, S; Manosuthi, W; Nilkamhang, S; Sukasem, C; Sungkanuparph, S; Thongyen, S1
Aweeka, F; Benson, CA; Grinsztejn, B; Havlir, DV; Hogg, E; Ive, P; Lu, D; Luetkemeyer, AF; Marzan, F; Rosenkranz, SL; Sanne, IM; Swindells, S1
Groth, J; Harrison, TS; Macallan, DC; Poulikakos, P; Wake, RM1
Aklillu, E; Gustafsson, LL; Luzze, H; Mukonzo, JK; Nakasujja, N; Ogwal-Okeng, J; Okwera, A; Sebuwufu, D; Waako, P1
Beumer, JH; Christner, SM; Gramignoli, R; Parise, RA; Pillai, VC; Rudek, MA; Strom, SC; Venkataramanan, R1
Bertrand, J; Blanc, FX; Borand, L; Chea, P; Chou, M; Mentré, F; Nay, KH; Taburet, AM; Verstuyft, C1
Bhavani, PK; Chandrasekar, C; Hannah, E; Kumar, H; Narendran, G; Padmapriyadarsini, C; Ponnuraja, C; Ramesh, C; Swaminathan, S; Tang, A; Wanke, C1
Ahmad, H; Chandrashekhar, R; Dhooria, S; Ekka, M; Khan, NH; Kumar, S; Pandey, RM; Raghunandan, P; Ranjan, S; Rewari, BB; Samantaray, JC; Sharma, SK; Sinha, S; Velpandian, T; Venkatesh, S1
Eley, B; Gous, H; Haas, DW; Maartens, G; McIlleron, HM; Merry, C; Moultrie, H; Nuttall, JJ; Ren, Y; Schomaker, M; Sinxadi, P; Smith, P1
Cao, L; Court, MH; Kurpewski, J; Kwara, A; Mahjoub, BD; Peloquin, CA; Poethke, P; Tashima, KT; Yang, H1
Chandrasekharan, C; Kumar, AK; Ponnuraja, C; Rajesh, L; Ramachandran, G; Ramesh, K; Swaminathan, S1
Chang, SY; Hung, CC; Kuo, CH; Lee, KY; Lin, SW; Liu, WC; Sun, HY; Tang, SY; Tsai, MS; Wu, BR1
Amin, A; Barau, C; Barrail-Tran, A; Baudin, E; Bhatt, NB; Bonnet, M; Furlan, V; Grinsztejn, B; Meggi, B; Silva, C; Taburet, AM1
Arya, V; Chan-Tack, KM; Jadhav, P; Kraft, J; Liu, J; Robertson, SM; Seo, S; Singer, ME; Struble, KA1
Almutairi, FE; Bourgea, J; Court, MH; Greenblatt, DJ; Hazarika, S; Klein, K; Kwara, A; Patten, CJ; Sheng, H; Zanger, UM1
Beumer, JH; Christner, SM; Parise, RA; Pillai, VC; Rudek, MA; Venkataramanan, R1
Chen, HJ; Deng, M; Jiang, HY; Ruan, B; Yang, Y; Zhang, MN1
Allen, R; Aweeka, F; Bao, J; Cramer, Y; Dooley, KE; Haas, DW; Koletar, SL; Luetkemeyer, AF; Marzan, F; Murray, S; Park, JG; Savic, R; Sutherland, D1
Aklillu, E; Bakari, M; Bertilsson, L; Burhenne, J; Diczfalusy, U; Janabi, M; Minzi, O; Mugusi, F; Mugusi, S; Ngaimisi, E; Riedel, KD; Sasi, P; Suda, A; Ueda, N1
Aklillu, E; Gustafson, LL; Mukonzo, JK; Nanzigu, S; Ogwal-Okeng, J; Waako, P1
Grinsztejn, B; Haas, DW; Havlir, DV; Lu, D; Luetkemeyer, AF; McIlleron, H; Rosenkranz, SL; Sanchez, J; Sanne, I; Ssemmanda, M1
Aderaye, G; Aklillu, E; Amogne, W; Bertilsson, L; Burhenne, J; Habtewold, A; Makonnen, E; Yimer, G1
Chonzi, P; Dhoro, M; Kadzirange, G; Masimirembwa, C; Ngara, B; Nhachi, C; Zvada, S1
Andersen, JW; Bao, Y; Benson, CA; Chaisson, RE; Fletcher, CV; Gupta, A; Kim, P; Mohapi, L; Mwelase, T; Podany, AT; Supparatpinyo, K; Swindells, S1
Beumer, JH; Christner, SM; Kiesel, BF; Parise, RA; Pillai, VC; Rudek, MA; Venkataramanan, R1
Beumont, M; Monshouwer, M; Ouwerkerk-Mahadevan, S; Snoeys, J1
Aklillu, E; Bisaso, RK; Gustafsson, LL; Mukonzo, JK; Ogwal-Okeng, J; Owen, JS1
Aderaye, G; Aklillu, E; Amogne, W; Bertilsson, L; Burhenne, J; Habtewold, A; Makonnen, E; Owen, JS; Yimer, G1
Budha, NR; Chen, Y; Dresser, M; Eppler, S; Ji, T; Jin, JY; Musib, L1
Mariana, N; Rusli, A1
De Jong, J; de Zwart, L; Mannaert, E; Monshouwer, M; Snoeys, J; Sukbuntherng, J1
Geiter, L; Mallikaarjun, S; Paccaly, A; Patil, S; Petersen, C; Shoaf, SE; Wells, C1
Aklillu, E; Bertilsson, L; Burhenne, J; Diczfalusy, U; Habtewold, A; Makonnen, E; Nylén, H; Yimer, G1
Adamson, J; Chirehwa, M; Denti, P; Essack, S; Govender, K; Kimba-Phongi, E; McIlleron, H; Naidoo, A; Naidoo, K; Padayatchi, N; Yende-Zuma, N1
Boffito, M; Flexner, CW; Maartens, G1
Aklillu, E; Aris, E; Bakari, M; Bertilsson, L; Burhenne, J; Janabi, M; Minzi, O; Mugusi, F; Mugusi, S; Ngaimisi, E; Sandstrom, E1
Boffito, M; Cerrone, M; Day-Weber, I; Fedele, S; Hill, A; McClure, M; Neary, M; Owen, A; Wang, X; Weaver, C1
Affolabi, D; Bah-Sow, O; Chirehwa, MT; Denti, P; McIlleron, H; Merle, C; Wiesner, L1
Aklillu, E; Bertilsson, L; Burhenne, J; Janabi, M; Kitabi, EN; Minzi, OMS; Mugusi, F; Mugusi, S; Sasi, P1
do Brasil, PEAA; Hadad, DJ; Maia, IR; Rolla, V; Sant'anna, FM; Schmaltz, CAS; Trajman, A; Xavier, MS1
Dandara, C; Swart, M1
Atwine, D; Barrail-Tran, A; Baudin, E; Bonnet, M; Furlan, V; Gelé, T; K T Nanjebe, D; Kananura, K; Kyohairwe, R; Muyindike, W; Mworozi, K; Nyehangane, D; Orikiriza, P; Taburet, AM; Verstuyft, C1
Aarnoutse, R; Aber, F; Denti, P; Dooley, KE; Lamorde, M; Musaazi, J; Nabisere, R; Sekaggya-Wiltshire, C; Sloan, DJ1
Dickinson, GL; Hall, SD; Kulanthaivel, P; Morse, BL; Posada, MM; Turner, PK1
Baker, P; Bao, Y; Benson, CA; Chaisson, RE; Fletcher, CV; Gupta, A; Haas, DW; Mohapi, L; Mwelase, N; Podany, AT; Supparatpinyo, K; Swindells, S1
Cabalu, TD; Dreyer, D; Fillgrove, KL; Iwamoto, M; Khalilieh, SG; Kuo, Y; Liu, Y; McClain, S; Sanchez, RI; Stoch, SA; Triantafyllou, I; Wenning, L; Yee, KL1
Aklillu, E; Amogne, W; Burhenne, J; Diczfalusy, U; Habtewold, A; Makonnen, E; Yimer, G; Zumla, A1
Chaturvedula, A; Cicali, B; Cristofoletti, R; Hoechel, J; Lingineni, K; Schmidt, S; Vozmediano, V; Wendl, T; Wiesinger, H1
Chang, JH; Li, R; Liu, L; Ly, JQ; Messick, K; Wong, S1
Carayannopoulos, LN; Kam, J; Krishna, G; Liu, L; Liu, M; Ogasawara, K; Palmisano, M; Surapaneni, S; Thomas, M; Xue, Y; Zhou, S1
Cohn, SE; Denti, P; Dooley, KE; Firnhaber, C; Francis, J; Godfrey, C; Kendall, MA; McIlleron, H; Mngqibisa, R; Wu, X1
Äbelö, A; Ashton, M; Bienvenu, E; Sundell, J1
Angira, F; Badal-Faesen, S; Baker, P; Cohn, SE; Denti, P; Francis, J; Haas, DW; Kendall, MA; Mawlana, S; McIlleron, H; Mngqibisa, R; Omoz-Oarhe, A; Robinson, JA; Samaneka, WP1
Badal-Faesen, S; Bryant, K; Campbell, K; Chaisson, RE; Dawson, R; Dooley, KE; Dorman, SE; Fletcher, CV; Johnson, JL; Kurbatova, EV; Lalloo, U; Martinson, N; Mayanja, H; Mohapi, L; Nahid, P; Pettit, A; Pham, M; Phillips, PPJ; Podany, AT; Samaneka, W; Scott, N; Sizemore, E; Swindells, S; Vernon, A; Whitworth, WC1
Aarnoutse, R; Aber, F; Alinaitwe, L; Buzibye, A; Denti, P; Dooley, KE; Gausi, K; Kengo, A; Lamorde, M; Musaazi, J; Nabisere, R; Najjemba, L; Nampala, J; Omali, D; Otaalo, B; Sekaggya-Wiltshire, C; Sloan, DJ1
Benson, CA; Chaisson, RE; Fletcher, CV; Gupta, A; Langat, D; Mohapi, L; Mwelase, N; Omoz-Oarhe, A; Pham, MM; Podany, AT; Samaneka, W; Supparatpinyo, K; Swindells, S1
Bryant, K; Chaisson, RE; Dawson, R; Dooley, KE; Dorman, SE; Johnson, JL; Kurbatova, E; Lalloo, UG; Mohapi, L; Muzanyi, G; Nahid, P; Pettit, AC; Phillips, PPJ; Podany, AT; Samaneka, W; Sanne, I; Savic, RM; Scott, N; Sizemore, E; Swindells, S; Vernon, A; Waja, Z1
Burhenne, J; Gottwalt, K; Haefeli, WE; Hohmann, N; Huisinga, W; Kloft, C; Meid, AD; Michelet, R; Mikus, G; Nassar, YM1
Badal-Faesen, S; Barr, E; Belaunzaran-Zamudio, PF; Cohn, SE; Gadama, L; Gatechompol, S; Godfrey, C; Jalil, EM; Mawlana, S; Mngqibisa, R; Olefsky, M; Pham, M; Podany, AT; Scarsi, KK; Smeaton, LM; Supparatpinyo, K; Woolley, E1
Battegay, M; Berton, M; Bettonte, S; Marzolini, C; Stader, F1
Agyemang, N; Badal-Faesen, S; Baker, P; Barr, E; Belaunzaran-Zamudio, PF; Cohn, SE; Gadama, L; Gatechompol, S; Godfrey, C; Haas, DW; Jalil, EM; Kayama, C; Mawlana, S; Mngqibisa, R; Olefsky, M; Pham, M; Podany, AT; Scarsi, KK; Smeaton, LM; Supparatpinyo, K; Van Schalkwyk, M; Woolley, E1
Fukami, T; Kazuki, Y; Kobayashi, K; Kurosawa, K; Nagaoka, M; Nakajima, M; Nakano, M; Sakai, Y; Takemoto, S; Yokoseki, I1
Aarnoutse, R; Chabala, C; Cotton, MF; Denti, P; Galileya, LT; Gibb, D; Hesseling, A; Lee, J; McIlleron, H; Njahira Mukui, I; Rabie, H; Turkova, A; Wasmann, RE; Zar, H1

Reviews

7 review(s) available for efavirenz and rifampin

ArticleYear
Membrane transporters in drug development.
    Nature reviews. Drug discovery, 2010, Volume: 9, Issue:3

    Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs

2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
    European journal of medicinal chemistry, 2022, Jul-05, Volume: 237

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells

2022
Are literature references sufficient for dose recommendations? An FDA case study of efavirenz and rifampin.
    Journal of clinical pharmacology, 2008, Volume: 48, Issue:4

    Topics: Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Databases, Bibliographic; Drug Interactions; Humans; Randomized Controlled Trials as Topic; Reference Standards; Rifampin; United States; United States Food and Drug Administration

2008
Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all.
    Expert opinion on drug metabolism & toxicology, 2010, Volume: 6, Issue:1

    Topics: Adult; Alkynes; Antitubercular Agents; Benzoxazines; Child; Cyclopropanes; Drug Interactions; HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis

2010
Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2014, Volume: 25

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials as Topic; Coinfection; Cyclopropanes; HIV Infections; Humans; Nevirapine; Rifampin; Treatment Outcome; Tuberculosis; Viral Load

2014
Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settings.
    Current opinion in HIV and AIDS, 2017, Volume: 12, Issue:4

    Topics: Adenine; Alanine; Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Interactions; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Rifampin; Tenofovir

2017

Trials

46 trial(s) available for efavirenz and rifampin

ArticleYear
Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.
    Clinical pharmacokinetics, 2002, Volume: 41, Issue:9

    Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Interactions; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Oxazines; Rifampin; Tuberculosis

2002
Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1.
    Journal of acquired immune deficiency syndromes (1999), 2004, Sep-01, Volume: 37, Issue:1

    Topics: Adult; Alkynes; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; India; Male; Middle Aged; Oxazines; Rifampin; Treatment Outcome; Tuberculosis

2004
Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin.
    AIDS (London, England), 2005, Sep-23, Volume: 19, Issue:14

    Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Female; HIV-1; Humans; Male; Middle Aged; Oxazines; Rifampin; RNA, Viral; Treatment Outcome; Tuberculosis

2005
Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results.
    AIDS (London, England), 2006, Jan-02, Volume: 20, Issue:1

    Topics: Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Body Weight; Cyclopropanes; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Oxazines; Rifampin; Treatment Outcome; Tuberculosis

2006
Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen.
    The Journal of antimicrobial chemotherapy, 2006, Volume: 58, Issue:5

    Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Interactions; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Mycobacterium tuberculosis; Oxazines; Prospective Studies; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis

2006
Concomitant use of nonnucleoside analogue reverse transcriptase inhibitors and rifampicin in TB/HIV type 1-coinfected patients.
    AIDS research and human retroviruses, 2008, Volume: 24, Issue:7

    Topics: Adult; Alkynes; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopropanes; Drug Administration Schedule; Drug Monitoring; Female; HIV Infections; HIV-1; Humans; Male; Nevirapine; Prospective Studies; Reverse Transcriptase Inhibitors; Rifampin; Treatment Outcome; Tuberculosis

2008
Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation.
    Journal of clinical pharmacology, 2008, Volume: 48, Issue:9

    Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Enzyme Induction; Female; Gene Frequency; Genetic Variation; Haplotypes; HIV Infections; Humans; Male; Middle Aged; Oxidoreductases, N-Demethylating; Phenotype; Prospective Studies; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis

2008
Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis.
    Journal of acquired immune deficiency syndromes (1999), 2009, Apr-15, Volume: 50, Issue:5

    Topics: Adolescent; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Drug Interactions; Female; HIV Infections; Humans; Linear Models; Male; Rifampin; Tuberculosis; Viral Load

2009
Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis.
    BMC medicine, 2009, Apr-22, Volume: 7

    Topics: Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; C-Reactive Protein; Child; Child, Preschool; Cyclopropanes; Female; HIV Infections; Humans; Male; Metabolic Clearance Rate; Rifampin; Ritonavir; Tuberculosis

2009
A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Jun-15, Volume: 48, Issue:12

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Plasma; Prospective Studies; Reverse Transcriptase Inhibitors; Rifampin; RNA, Viral; Treatment Outcome; Tuberculosis; Viral Load

2009
Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa.
    Antiviral therapy, 2009, Volume: 14, Issue:5

    Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Polymorphism, Genetic; Reverse Transcriptase Inhibitors; Rifampin; Risk Factors; South Africa; Tuberculosis

2009
Pharmacokinetic interaction between efavirenz and rifampicin in healthy volunteers.
    International journal of clinical pharmacology and therapeutics, 2011, Volume: 49, Issue:2

    Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Area Under Curve; Benzoxazines; Biological Availability; Cyclopropanes; Drug Interactions; Humans; Male; Middle Aged; Rifampin

2011
Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:4

    Topics: Adult; Alkynes; Benzoxazines; Chromatography, Liquid; Cross-Over Studies; Cyclopropanes; Double-Blind Method; Female; Glucuronidase; Glucuronides; Humans; Male; Rifampin; Tandem Mass Spectrometry; Young Adult

2011
Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:7

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Black People; Chromatography, High Pressure Liquid; Cross-Over Studies; Cyclopropanes; Female; Genotype; Humans; Male; Middle Aged; Rifampin; White People; Young Adult

2011
Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?
    Antiviral therapy, 2011, Volume: 16, Issue:4

    Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Reverse Transcriptase Inhibitors; Rifampin; South Africa; Treatment Outcome; Tuberculosis

2011
Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen.
    The Southeast Asian journal of tropical medicine and public health, 2011, Volume: 42, Issue:3

    Topics: Adult; Alkynes; Antibiotics, Antitubercular; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Hyperbilirubinemia; Liver Function Tests; Logistic Models; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Rifampin; Risk Factors; Thailand; Tuberculosis; Young Adult

2011
Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis.
    Clinical pharmacology and therapeutics, 2011, Volume: 90, Issue:3

    Topics: Alkynes; Alleles; Anti-HIV Agents; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Drug Interactions; Enzyme Induction; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Oxidoreductases, N-Demethylating; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis

2011
The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis.
    European journal of clinical pharmacology, 2012, Volume: 68, Issue:5

    Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Biotransformation; Cyclopropanes; Drug Administration Schedule; Drug Interactions; Female; Half-Life; HIV Infections; Humans; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Reverse Transcriptase Inhibitors; Rifampin; South Africa; Tuberculosis; Young Adult

2012
Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
    Antiviral therapy, 2013, Volume: 18, Issue:1

    Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Ethambutol; Female; HIV Infections; Humans; Isoniazid; Male; Organophosphonates; Oxazines; Pyrazinamide; Reverse Transcriptase Inhibitors; Rifampin; Treatment Outcome; Tuberculosis, Pulmonary

2013
Influence of ABCB-1 C3435T polymorphisms on plasma nevirapine and efavirenz levels and their effects on virologic and immunological outcomes in HIV/TB co-infected Thai adults under anti-retroviral therapy.
    The Southeast Asian journal of tropical medicine and public health, 2012, Volume: 43, Issue:1

    Topics: Adult; Alkynes; Analysis of Variance; Antiretroviral Therapy, Highly Active; Antitubercular Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Nevirapine; Polymorphism, Genetic; Real-Time Polymerase Chain Reaction; Rifampin; Thailand; Tuberculosis; Viral Load

2012
Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia.
    The Journal of infectious diseases, 2014, Feb-01, Volume: 209, Issue:3

    Topics: Alkynes; Anti-HIV Agents; Antitubercular Agents; Aryl Hydrocarbon Hydroxylases; Arylamine N-Acetyltransferase; Benzoxazines; Cambodia; Chromatography, Liquid; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Interactions; HIV Infections; Humans; Isoniazid; Lamivudine; Plasma; Polymorphism, Single Nucleotide; Rifampin; Spectrophotometry, Ultraviolet; Stavudine; Tuberculosis

2014
Early changes in hepatic function among HIV-tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy.
    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2013, Volume: 17, Issue:12

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; CD4 Lymphocyte Count; Coinfection; Cyclopropanes; Female; HIV Infections; Humans; Liver; Liver Function Tests; Male; Nevirapine; Rifampin; Time Factors; Treatment Outcome; Tuberculosis; Viral Load

2013
Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study.
    BMC infectious diseases, 2013, Oct-17, Volume: 13

    Topics: Adult; Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Coinfection; Cyclopropanes; Female; HIV Infections; Humans; India; Male; Middle Aged; Nevirapine; Pilot Projects; Rifampin; Tuberculosis

2013
Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance.
    Pharmacotherapy, 2014, Volume: 34, Issue:3

    Topics: Adult; Alkynes; Benzoxazines; Cross-Over Studies; Cyclopropanes; Drug Interactions; Female; Genetic Variation; Genotype; Humans; Liver-Specific Organic Anion Transporter 1; Male; Metabolic Clearance Rate; Middle Aged; Organic Anion Transporters; Rifampin

2014
Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:6

    Topics: Adult; Alkynes; Antitubercular Agents; Benzoxazines; Coinfection; Cyclopropanes; Female; Half-Life; HIV Infections; Humans; Isoniazid; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Rifampin; Treatment Outcome; Tuberculosis; Young Adult

2014
Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:9

    Topics: Adult; Alkynes; Antitubercular Agents; Antiviral Agents; Benzoxazines; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Humans; Lopinavir; Male; Middle Aged; Nitroimidazoles; Pharmacogenetics; Rifampin; Ritonavir; Young Adult

2014
Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.
    Pharmacogenomics, 2015, Volume: 16, Issue:10

    Topics: Adult; Africa South of the Sahara; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Coinfection; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infections; Humans; Male; Pharmacogenetics; Prospective Studies; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis

2015
Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015, Oct-15, Volume: 61, Issue:8

    Topics: Administration, Oral; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Isoniazid; Male; Reverse Transcriptase Inhibitors; Rifampin; RNA, Viral; Tuberculosis

2015
Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.
    Journal of clinical pharmacology, 2016, Volume: 56, Issue:12

    Topics: Adult; Alkynes; Antitubercular Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2B6 Inducers; Drug Therapy, Combination; Ethiopia; Female; HIV Infections; Humans; Male; Middle Aged; Rifampin; Time Factors; Treatment Outcome; Tuberculosis; Young Adult

2016
Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling.
    Clinical pharmacology and therapeutics, 2016, Volume: 100, Issue:5

    Topics: Adenine; Alkynes; Azithromycin; Benzoxazines; Carbamazepine; Cyclopropanes; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Dosage Calculations; Drug Interactions; Fluvoxamine; Humans; Ketoconazole; Male; Models, Biological; Piperidines; Pyrazoles; Pyrimidines; Rifampin

2016
Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:10

    Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Drug Combinations; Drug Interactions; Ethambutol; Female; Healthy Volunteers; Humans; Isoniazid; Male; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifampin

2016
Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.
    The Journal of antimicrobial chemotherapy, 2017, 05-01, Volume: 72, Issue:5

    Topics: Adult; Africa; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Coinfection; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Fluoroquinolones; HIV Infections; Humans; Male; Moxifloxacin; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis, Pulmonary

2017
Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid.
    The Journal of antimicrobial chemotherapy, 2019, 01-01, Volume: 74, Issue:1

    Topics: Adolescent; Adult; Africa, Western; Aged; Aged, 80 and over; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; Blood Chemical Analysis; Cyclopropanes; Drug Interactions; Female; HIV Infections; Humans; Inactivation, Metabolic; Isoniazid; Male; Middle Aged; Randomized Controlled Trials as Topic; Rifampin; Tuberculosis; Young Adult

2019
Daily 800 mg versus 600 mg Efavirenz for HIV Patients Treating Tuberculosis with a Rifampicin-Based Regimen: An Open Label Randomized Controlled Trial.
    BioMed research international, 2018, Volume: 2018

    Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Male; Middle Aged; Rifampin; Tuberculosis

2018
Effect of high-dose rifampicin on efavirenz pharmacokinetics: drug-drug interaction randomized trial.
    The Journal of antimicrobial chemotherapy, 2020, 05-01, Volume: 75, Issue:5

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; HIV Infections; Humans; Pharmaceutical Preparations; Rifampin

2020
Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
    Trials, 2020, Feb-13, Volume: 21, Issue:1

    Topics: Adult; Alkynes; Antibiotics, Antitubercular; Antitubercular Agents; Benzoxazines; Clinical Trials, Phase II as Topic; Coinfection; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2B6 Inducers; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Randomized Controlled Trials as Topic; Rifampin; Treatment Outcome; Tuberculosis; Uganda

2020
Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine.
    Pharmacogenetics and genomics, 2021, Volume: 31, Issue:1

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Arylamine N-Acetyltransferase; Benzoxazines; Cyclopropanes; Drug Synergism; HIV Infections; Humans; Isoniazid; Male; Middle Aged; Nevirapine; Pharmacogenetics; Rifampin; Young Adult

2021
Physiologically Based Pharmacokinetic Modeling of Doravirine and Its Major Metabolite to Support Dose Adjustment With Rifabutin.
    Journal of clinical pharmacology, 2021, Volume: 61, Issue:3

    Topics: Adult; Alkynes; Benzoxazines; Computer Simulation; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Male; Middle Aged; Models, Biological; Pyridones; Reverse Transcriptase Inhibitors; Rifabutin; Rifampin; Triazoles; Young Adult

2021
Early or deferred initiation of efavirenz during rifampicin-based TB therapy has no significant effect on CYP3A induction in TB-HIV infected patients.
    British journal of pharmacology, 2021, Volume: 178, Issue:16

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP3A; HIV Infections; Humans; Longitudinal Studies; Rifampin; Tuberculosis

2021
Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants.
    Cancer chemotherapy and pharmacology, 2021, Volume: 88, Issue:3

    Topics: Adult; Alkynes; Area Under Curve; Benzoxazines; Chromatography, Liquid; Cyclopropanes; Cytochrome P-450 CYP3A Inducers; Drug Interactions; Female; Humans; Janus Kinase 2; Male; Middle Aged; Protein Kinase Inhibitors; Pyrrolidines; Rifampin; Sulfonamides; Tandem Mass Spectrometry; Young Adult

2021
Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis.
    Pharmacogenetics and genomics, 2022, 01-01, Volume: 32, Issue:1

    Topics: Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Drug Interactions; Female; HIV Infections; Humans; Isoniazid; Medroxyprogesterone Acetate; Pharmacogenetics; Rifampin; Tuberculosis

2022
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 09-10, Volume: 75, Issue:4

    Topics: Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Moxifloxacin; Rifampin; Tuberculosis

2022
Decreased Dolutegravir and Efavirenz Concentrations With Preserved Virological Suppression in Patients With Tuberculosis and Human Immunodeficiency Virus Receiving High-Dose Rifampicin.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023, 02-08, Volume: 76, Issue:3

    Topics: Anti-HIV Agents; Benzoxazines; HIV; HIV Infections; Humans; Rifampin; Tuberculosis

2023
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023, 02-08, Volume: 76, Issue:3

    Topics: Antitubercular Agents; Drug Therapy, Combination; HIV; HIV Infections; Humans; Isoniazid; Moxifloxacin; Rifampin; Tuberculosis; Tuberculosis, Pulmonary

2023
Quantification of the Time Course of CYP3A Inhibition, Activation, and Induction Using a Population Pharmacokinetic Model of Microdosed Midazolam Continuous Infusion.
    Clinical pharmacokinetics, 2022, Volume: 61, Issue:11

    Topics: Administration, Oral; Area Under Curve; Cytochrome P-450 CYP3A; Drug Interactions; Humans; Midazolam; Pharmaceutical Preparations; Rifampin; Voriconazole

2022
Pharmacokinetics of dose-adjusted levonorgestrel emergency contraception combined with efavirenz-based antiretroviral therapy or rifampicin-containing tuberculosis regimens.
    Contraception, 2023, Volume: 121

    Topics: Adolescent; Benzoxazines; Contraception, Postcoital; Female; HIV Infections; Humans; Levonorgestrel; Rifampin; Tuberculosis

2023

Other Studies

61 other study(ies) available for efavirenz and rifampin

ArticleYear
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
    Journal of medicinal chemistry, 2008, Oct-09, Volume: 51, Issue:19

    Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship

2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
    Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10

    Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection

2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
New drugs 99, Part III.
    Nursing, 1999, Volume: 29, Issue:6

    Topics: Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antiviral Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Monitoring; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Etidronic Acid; Humans; Infliximab; Leprostatic Agents; Osteitis Deformans; Oxazines; Rifampin; Risedronic Acid; Thalidomide; Thionucleotides; Trastuzumab

1999
Simultaneous determination of rifampicin and efavirenz in plasma.
    Therapeutic drug monitoring, 2002, Volume: 24, Issue:5

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; HIV Infections; Humans; Male; Middle Aged; Oxazines; Rifampin; Tuberculosis

2002
Efficacy and safety of Efavirenz in HIV patients on Rifampin for tuberculosis.
    The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2004, Volume: 8, Issue:3

    Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Drug Interactions; Female; HIV Infections; Humans; Isoniazid; Male; Middle Aged; Oxazines; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary

2004
Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital.
    Journal of clinical pharmacology, 2004, Volume: 44, Issue:11

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cells, Cultured; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Enzyme Induction; Hepatocytes; Humans; Oxazines; Phenobarbital; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Rifampin; RNA, Messenger

2004
Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all.
    AIDS (London, England), 2005, Sep-23, Volume: 19, Issue:14

    Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Oxazines; Rifampin; Tuberculosis

2005
False-positive results in urine drug screening in healthy volunteers participating in phase 1 studies with efavirenz and rifampin.
    Therapeutic drug monitoring, 2006, Volume: 28, Issue:2

    Topics: Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Clinical Trials, Phase I as Topic; Cyclopropanes; Dronabinol; Drug Monitoring; False Positive Reactions; Humans; Oxazines; Rifampin

2006
Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.
    The Journal of antimicrobial chemotherapy, 2006, Volume: 58, Issue:6

    Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; CD4 Lymphocyte Count; Chromatography, High Pressure Liquid; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Male; Oxazines; Rifampin; Treatment Outcome; Tuberculosis, Pulmonary; Viral Load

2006
Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients.
    Current HIV research, 2007, Volume: 5, Issue:3

    Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Biological Availability; Cyclopropanes; Drug Interactions; Female; HIV Infections; Humans; Male; Prospective Studies; Rifampin; Tuberculosis

2007
Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.
    HIV medicine, 2008, Volume: 9, Issue:5

    Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Antitubercular Agents; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Nevirapine; Retrospective Studies; Reverse Transcriptase Inhibitors; Rifampin; Treatment Outcome; Tuberculosis; Viral Load

2008
Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.
    JAMA, 2008, Aug-06, Volume: 300, Issue:5

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Female; HIV Infections; Humans; Male; Nevirapine; Rifampin; South Africa; Treatment Failure; Treatment Outcome; Tuberculosis; Viral Load

2008
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.
    Antiviral therapy, 2008, Volume: 13, Issue:5

    Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Black People; Body Weight; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Rifampin; Viral Load; White People

2008
Efavirenz-rifampicin interaction: therapeutic drug monitoring to efavirenz dosage optimization in HIV/TBC patients.
    AIDS (London, England), 2008, Nov-30, Volume: 22, Issue:18

    Topics: Adult; Alkynes; Antibiotics, Antitubercular; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Monitoring; Female; HIV Infections; Humans; Male; Middle Aged; Pharmacogenetics; Reverse Transcriptase Inhibitors; Rifampin; Treatment Outcome; Tuberculosis

2008
CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:3

    Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Therapy, Combination; Female; Geography; HIV Infections; HIV-1; Humans; India; Male; Middle Aged; Oxidoreductases, N-Demethylating; Polymorphism, Genetic; Rifampin; Tuberculosis

2009
Efavirenz dose reduction to 200 mg once daily in a patient treated with rifampicin.
    AIDS (London, England), 2009, Mar-27, Volume: 23, Issue:6

    Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Cyclopropanes; Drug Interactions; Humans; Male; Middle Aged; Rifampin; Tuberculosis

2009
Efavirenz and nevirapine interactions with rifampicin: resolving the dilemmas?
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Jun-15, Volume: 48, Issue:12

    Topics: Alkynes; Anti-Bacterial Agents; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; HIV Infections; Humans; Nevirapine; Rifampin; Tuberculosis

2009
Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:10

    Topics: Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Body Weight; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; Humans; Male; Multivariate Analysis; Rifampin; Tuberculosis

2009
In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype.
    British journal of clinical pharmacology, 2011, Volume: 71, Issue:4

    Topics: Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Body Weight; Computer Simulation; Cyclopropanes; Cytochrome P-450 CYP2B6; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Forecasting; HIV Infections; Humans; Models, Theoretical; Oxidoreductases, N-Demethylating; Phenotype; Rifampin; Tuberculosis

2011
Serum Nevirapine and Efavirenz concentrations and effect of concomitant rifampicin in HIV infected children on antiretroviral therapy.
    Indian pediatrics, 2011, Volume: 48, Issue:12

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Cross-Sectional Studies; Cyclopropanes; Drug Interactions; Drug Monitoring; Female; HIV Infections; Humans; Male; Nevirapine; Rifampin

2011
Simultaneous determination of efavirenz, rifampicin and its metabolite desacetyl rifampicin levels in human plasma.
    Journal of pharmaceutical and biomedical analysis, 2011, Dec-05, Volume: 56, Issue:4

    Topics: Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Monitoring; Drug Stability; HIV Infections; Humans; Reference Standards; Reproducibility of Results; Rifampin; Sensitivity and Specificity; Tuberculosis

2011
Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients.
    PloS one, 2011, Volume: 6, Issue:12

    Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Biomarkers, Tumor; Case-Control Studies; Comorbidity; Cyclopropanes; Female; Genotype; HIV Infections; Humans; Liver; Male; Middle Aged; Pharmacogenetics; Prospective Studies; Rifampin; Time Factors; Tuberculosis

2011
Treatment challenges in co-infected HIV and TB children.
    Indian pediatrics, 2011, Volume: 48, Issue:12

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Male; Nevirapine; Rifampin

2011
The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers.
    British journal of clinical pharmacology, 2013, Volume: 75, Issue:2

    Topics: Adult; Alkynes; Area Under Curve; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Female; Humans; Ketoconazole; Male; Middle Aged; Oligopeptides; Rifampin

2013
Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:2

    Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Interactions; Ethambutol; Female; Genotype; HIV Infections; Humans; Isoniazid; Lamivudine; Male; Middle Aged; Organophosphonates; Oxidoreductases, N-Demethylating; Pharmacogenetics; Polymorphism, Single Nucleotide; Pyrazinamide; Reverse Transcriptase Inhibitors; Rifampin; Tenofovir; Tuberculosis; Young Adult

2013
Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 57, Issue:4

    Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Body Weight; Cyclopropanes; Drug Interactions; Female; HIV Infections; Humans; Male; Rifampin; Treatment Outcome; Tuberculosis; Viral Load

2013
Evaluation of a pro-active strategy for managing tuberculosis-HIV co-infection in a UK tertiary care setting.
    International journal of STD & AIDS, 2013, Volume: 24, Issue:4

    Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Coinfection; Cyclopropanes; Drug Monitoring; HIV Infections; Humans; Middle Aged; Mycobacterium; Prospective Studies; Rifampin; Time Factors; Treatment Outcome; Tuberculosis; United Kingdom; Viral Load

2013
Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.
    BMC infectious diseases, 2013, Jun-04, Volume: 13

    Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cognitive Dysfunction; Constitutive Androstane Receptor; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Female; Gene Frequency; Hallucinations; HIV Infections; Humans; Kaplan-Meier Estimate; Male; Memory Disorders; Mental Disorders; Prospective Studies; Rifampin; Sleep Arousal Disorders; Tuberculosis; Uganda

2013
Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.
    Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:10

    Topics: 14-alpha Demethylase Inhibitors; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Erlotinib Hydrochloride; Female; Half-Life; Hepatocytes; HIV Infections; HIV Protease Inhibitors; Humans; Ketoconazole; Male; Middle Aged; Neoplasms; Nucleic Acid Synthesis Inhibitors; Quinazolines; Rifampin; Ritonavir

2013
Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype.
    AIDS (London, England), 2013, Jul-31, Volume: 27, Issue:12

    Topics: Alkynes; Anti-HIV Agents; Antitubercular Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Interactions; Female; Genotype; HIV Infections; Humans; Male; Plasma; Rifampin; Tuberculosis

2013
Lack of association between plasma levels of non-nucleoside reverse transcriptase inhibitors & virological outcomes during rifampicin co-administration in HIV-infected TB patients.
    The Indian journal of medical research, 2013, Volume: 138, Issue:6

    Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genetic Association Studies; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis

2013
Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy.
    PloS one, 2014, Volume: 9, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Alkynes; Anti-HIV Agents; Antitubercular Agents; Aryl Hydrocarbon Hydroxylases; Asian People; Benzoxazines; Body Weight; China; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Monitoring; Drug Therapy, Combination; Ethnicity; Female; HIV Infections; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polymorphism, Single Nucleotide; Rifampin; Tuberculosis; Young Adult

2014
Why did the FDA approve efavirenz 800 mg when co-administered with rifampin?
    International journal of clinical pharmacology and therapeutics, 2014, Volume: 52, Issue:6

    Topics: Alkynes; Antibiotics, Antitubercular; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Coinfection; Computer Simulation; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Administration Schedule; Drug Approval; Drug Dosage Calculations; Drug Interactions; Genotype; HIV Infections; Humans; Models, Biological; Phenotype; Polypharmacy; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis; United States; United States Food and Drug Administration

2014
Isoniazid mediates the CYP2B6*6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:7

    Topics: Alkynes; Antitubercular Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2A6; Cytochrome P-450 CYP2B6; Drug Interactions; Enzyme Activation; Ethambutol; Humans; Hydroxylation; Isoniazid; Microsomes, Liver; Pyrazinamide; Rifampin

2014
Potential interactions between HIV drugs, ritonavir and efavirenz and anticancer drug, nilotinib--a study in primary cultures of human hepatocytes that is applicable to HIV patients with cancer.
    Journal of clinical pharmacology, 2014, Volume: 54, Issue:11

    Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Antifungal Agents; Antineoplastic Agents; Area Under Curve; Benzoxazines; Cells, Cultured; Cyclopropanes; Drug Interactions; Female; Half-Life; Hepatocytes; Humans; Ketoconazole; Male; Middle Aged; Pyrimidines; Rifampin; Ritonavir; Young Adult

2014
Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment.
    The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:12

    Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Female; Genotype; HIV Infections; Humans; Hydroxycholesterols; Male; Middle Aged; Rifampin; Tuberculosis

2014
CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure.
    Pharmacogenomics, 2014, Volume: 15, Issue:11

    Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Benzoxazines; Coinfection; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genetic Variation; Genotype; HIV Infections; Humans; Male; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis

2014
Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015, Jun-15, Volume: 60, Issue:12

    Topics: Alkynes; Antitubercular Agents; Arylamine N-Acetyltransferase; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infections; Humans; Male; Peru; Pharmacogenetics; Rifampin; South Africa; Tuberculosis; Uganda

2015
CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.
    BMC pharmacology & toxicology, 2015, Mar-27, Volume: 16

    Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Alleles; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B; Benzoxazines; Body Weight; Case-Control Studies; Cyclopropanes; Cytochrome P-450 CYP2A6; Cytochrome P-450 CYP2B6; Drug Interactions; Female; Hallucinations; Headache; Humans; Male; Models, Biological; Rifampin; Sex Characteristics; Sleep Wake Disorders; Tuberculosis; Zimbabwe

2015
Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.
    British journal of clinical pharmacology, 2015, Volume: 80, Issue:5

    Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Hepatocytes; Humans; Imatinib Mesylate; Ketoconazole; Male; Middle Aged; Primary Cell Culture; Rifampin; Ritonavir; Young Adult

2015
Mechanistic understanding of the nonlinear pharmacokinetics and intersubject variability of simeprevir: A PBPK-guided drug development approach.
    Clinical pharmacology and therapeutics, 2016, Volume: 99, Issue:2

    Topics: Alkynes; Antiviral Agents; Benzoxazines; Cyclopropanes; Cyclosporine; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Erythromycin; Hepatitis C; Humans; Liver; Liver-Specific Organic Anion Transporter 1; Nonlinear Dynamics; Organic Anion Transporters; Rifampin; Ritonavir; Simeprevir; Viral Nonstructural Proteins

2016
CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population.
    Pharmacogenomics, 2016, Volume: 17, Issue:6

    Topics: Adult; Africa South of the Sahara; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Coinfection; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis; Viral Load; Zidovudine

2016
Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
    Clinical pharmacokinetics, 2016, Volume: 55, Issue:11

    Topics: Administration, Oral; Alkynes; Area Under Curve; Azetidines; Benzoxazines; Computer Simulation; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Diltiazem; Drug Interactions; Erythromycin; Fluvoxamine; Humans; Models, Biological; Piperidines; Retrospective Studies; Rifampin

2016
Efavirenz Plasma Concentrations and HIV Viral Load in HIV/AIDS-tuberculosis Infection Patients Treated with Rifampicin.
    Acta medica Indonesiana, 2016, Volume: 48, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; CD4 Lymphocyte Count; Central Nervous System; Cyclopropanes; Female; Humans; Male; Middle Aged; Rifampin; Tuberculosis; Viral Load; Young Adult

2016
Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency: A prospective cohort study.
    Medicine, 2016, Volume: 95, Issue:34

    Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; Cholesterol; Cohort Studies; Cyclopropanes; Ethiopia; Female; HIV Infections; Humans; Male; Prevalence; Prospective Studies; Rifampin; Risk Factors; Treatment Outcome; Tuberculosis, Pulmonary; Vitamin D; Vitamin D Deficiency

2016
Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.
    European journal of clinical pharmacology, 2018, Volume: 74, Issue:11

    Topics: Adult; Africa South of the Sahara; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Mental Disorders; Pharmacogenetics; Prospective Studies; Rifampin; Tuberculosis

2018
Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019, 01-18, Volume: 68, Issue:3

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Isoniazid; Male; Middle Aged; Rifampin; Viral Load; Young Adult

2019
Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype.
    Scientific reports, 2018, 11-05, Volume: 8, Issue:1

    Topics: Adult; Alkynes; Benzoxazines; Coinfection; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Interactions; Female; Genotype; HIV Infections; Humans; Male; Middle Aged; Rifampin; Tanzania; Tissue Distribution; Tuberculosis

2018
MicroRNA Mediated Changes in Drug Metabolism and Target Gene Expression by Efavirenz and Rifampicin
    Omics : a journal of integrative biology, 2019, Volume: 23, Issue:10

    Topics: Alkynes; Benzoxazines; Cell Line, Tumor; Constitutive Androstane Receptor; Cyclopropanes; Gene Expression Regulation; Humans; Inactivation, Metabolic; MicroRNAs; Reverse Transcription; Rifampin; RNA, Messenger

2019
Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling.
    Journal of clinical pharmacology, 2020, Volume: 60, Issue:7

    Topics: Administration, Oral; Adult; Aged; Alkynes; Aminopyridines; Area Under Curve; Benzimidazoles; Benzoxazines; Bosentan; Clarithromycin; Computer Simulation; Cyclin-Dependent Kinases; Cyclopropanes; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Diltiazem; Drug Interactions; Female; Healthy Volunteers; Humans; Itraconazole; Ketoconazole; Male; Middle Aged; Modafinil; Models, Biological; Rifampin; Verapamil

2020
Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling.
    CPT: pharmacometrics & systems pharmacology, 2021, Volume: 10, Issue:1

    Topics: Adult; Alkynes; Benzoxazines; Body Mass Index; Carbamazepine; Clarithromycin; Computer Simulation; Contraceptives, Oral, Combined; Cyclopropanes; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Combinations; Drug Interactions; Ethinyl Estradiol; Female; Humans; Itraconazole; Levonorgestrel; Models, Biological; Obesity; Rifampin; Sex Hormone-Binding Globulin

2021
Investigating the Utility of Humanized Pregnane X Receptor-Constitutive Androstane Receptor-CYP3A4/7 Mouse Model to Assess CYP3A-Mediated Induction.
    Drug metabolism and disposition: the biological fate of chemicals, 2021, Volume: 49, Issue:7

    Topics: Alkynes; Animals; Benzoxazines; Constitutive Androstane Receptor; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Drug Evaluation, Preclinical; Drug Interactions; Feasibility Studies; Female; Humans; Mice; Mice, Transgenic; Microsomes, Liver; Pioglitazone; Pregnane X Receptor; Rifampin; Species Specificity; Triazolam

2021
A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment.
    Clinical pharmacology and therapeutics, 2021, Volume: 110, Issue:4

    Topics: Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Contraceptive Agents, Hormonal; Contraceptive Effectiveness; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Drug Interactions; Female; HIV Infections; Humans; Isoniazid; Lopinavir; Medroxyprogesterone Acetate; Nelfinavir; Rifampin; Ritonavir; Tuberculosis

2021
Effect of efavirenz-based ART on the pharmacokinetics of rifampicin and its primary metabolite in patients coinfected with TB and HIV.
    The Journal of antimicrobial chemotherapy, 2021, 10-11, Volume: 76, Issue:11

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Chromatography, Liquid; Coinfection; Cyclopropanes; HIV Infections; Humans; Liver-Specific Organic Anion Transporter 1; Rifampin; Tandem Mass Spectrometry; Tuberculosis

2021
Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing.
    Antimicrobial agents and chemotherapy, 2022, 09-20, Volume: 66, Issue:9

    Topics: Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Isoniazid; Nevirapine; Rifampin

2022
Management of Drug Interactions with Inducers: Onset and Disappearance of Induction on Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyltransferase 1A1 Substrates.
    European journal of drug metabolism and pharmacokinetics, 2023, Volume: 48, Issue:4

    Topics: Cytochrome P-450 CYP3A; Drug Interactions; Female; Glucuronosyltransferase; Humans; Male; Raltegravir Potassium; Rifabutin; Rifampin

2023
Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis.
    Pharmacogenetics and genomics, 2023, 08-01, Volume: 33, Issue:6

    Topics: Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Contraception, Postcoital; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Female; Genotype; HIV Infections; Humans; Isoniazid; Levonorgestrel; Pharmacogenetics; Rifampin; Tuberculosis

2023
ncBAF enhances PXR-mediated transcriptional activation in the human and mouse liver.
    Biochemical pharmacology, 2023, Volume: 215

    Topics: Animals; Cytochrome P-450 CYP3A; Hepatocytes; Humans; Lipids; Liver; Mice; Mice, Inbred C57BL; Pregnane X Receptor; Receptors, Steroid; Rifampin; Transcription Factors; Transcriptional Activation

2023
Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis.
    PLoS medicine, 2023, Volume: 20, Issue:11

    Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Female; HIV; HIV Infections; Humans; Infant; Infant, Newborn; Isoniazid; Lopinavir; Male; Pyrazinamide; Rifampin; Ritonavir; Tuberculosis

2023
chemdatabank.com